English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Primary integrase resistance transmission has been exceedingly rare and has been reported only in the context of multi-drug resistance, which is consistent with the initial use of integrase inhibitors, since raltegravir was approved in 2007 for use in treatment experienced individuals. However, over the years, integrase inhibitors have moved to first-line recommended therapy due to the efficacy, tolerability, and the availability of multiple single tablet integrase inhibitor-based regimens. The DHHS guidelines have recommended integrase inhibitors to be the predominant recommended class of first-line treatment regimens since 2015. Despite predictions that primary integrase inhibitor resistance transmission would increase, none have reported integrase inhibitor single-class resistant transmitted virus, and a recent presentation at ICAAC 2015 by Monogram showed a lack of transmitted primary integrase inhibitor resistance at 13 AHF sites throughout California. However, integrase resistance may not have been uncovered, as active integrase testing has not been routinely performed in ART-naïve HIV-1infected individuals in higher risk communities. This report describes two cases of antiretroviral naïve individuals who were infected with integraseresistant viruses without other class resistance, including the first reported case of primary elvitegravir resistance transmission. Furthermore, this report highlights that should HIV-1 integrase resistance testing be performed prior to starting HAART, that integrase genotyping, rather than phenotyping should be performed as phenotyping may miss resistance in the setting of genotypic mixtures.

open forum infectious diseases

Two Reported Cases of Only Primary Integrase Inhibitor Drug-Class Resistance Transmission including the First Reported Case of Primary Elvitegravir Resistance Transmission